Tumor Immunopharmacology
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 9 September 2024 | Viewed by 141
Special Issue Editor
Interests: pharmacology; cancer cell biology; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Modulation of the immune system has proven to be an effective way to reduce the progression of multiple tumors. Thus, the discovery of new immunotherapeutic agents is a rapidly growing field. At present, the arsenal of immunomodulators with potential clinical application includes multiple modalities of antibodies, small compounds and peptides targeting immune signaling pathways, vaccines and adoptive cell transfer.
This Special Issue will provide a comprehensive overview of the development of new immunotherapeutic agents for cancer treatment in the pre-clinical, translational and clinical settings. We invite authors to submit original research or review articles that analyze the mechanism of action, efficacy, safety and/or pharmacokinetics of immunotherapeutics in relevant models of neoplastic diseases.
Dr. Marco A. Velasco-Velázquez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- immunomodulation
- drug development
- cytokine receptor antagonist
- T-cell based therapies
- therapeutic antibodies
- drug delivery
- cancer vaccine
